Recon: Pfizer expected to seek broader authorization for COVID booster; Regeneron says antibody reduces risk of contracting COVID for up to 8 months
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy